Moleculin Biotech, Inc.
- Biotech or pharma, therapeutic R&D
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. Lead asset Annamycin has demonstrated 50% CR rate in 2L AML. The MiRACLE Phase 3 pivotal clinical trial has begun treating patients, with an interim data readout expected Q4 2025. A recently concluded Phase 1/2 trial in advanced STS demonstrated 13.5 months mOS, supporting further investigation in STS and other solid tumor indications.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}